{"id":18060,"date":"2021-10-07T15:41:38","date_gmt":"2021-10-07T13:41:38","guid":{"rendered":"https:\/\/www.izb-online.de\/6-munich-life-science-pitch-day-im-izb-mit-ueber-20-investoren\/"},"modified":"2021-10-08T09:18:39","modified_gmt":"2021-10-08T07:18:39","slug":"6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/","title":{"rendered":"6th Munich Life Science Pitch Day at the IZB with over 20 investors"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

6th Munich Life Science Pitch Day at the IZB with over 20 investors<\/strong><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]October 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text el_class=”gco-magazine-copyright”]<\/p>\n

\n
\n
\n
<\/div>\n
\n
<\/div>\n
\n

You are currently viewing a placeholder content from YouTube<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p>\n

More Information<\/a> <\/div>\n

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div><\/div><\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]On September 30, 2021, the Munich Life Science Pitch Day was held again as a Face2Face event at the Innovation and Start-up Center after the Long Corona Break. This event takes place annually in cooperation with the High-Tech Gr\u00fcnderfonds (HTGF), Bayer AG, Boehringer Ingelheim and the Innovations- und Gr\u00fcnderzentrum Biotechnologie (IZB). This year, 35 project teams from the life science sector applied. 10 start-ups had the opportunity to present their innovative drug development projects to renowned venture capital companies.\u00a0 <\/strong><\/p>\n

The following investors attended this event: Abbvie, Apollo Health Ventures, Bayer, Bayern Capital, BioMed Partners, bmp Ventures, Boehringer Ingelheim, Coparion, Forbion Capital Partners, Hadean Ventures, HTGF, KURMA Partners, Long VC, LSP, mbc, Maximon, Medi Ventures, Occident Group, Seventure, TVM Capital, Vantage Value, Vesalius Biocapital and Wellington Partners.<\/p>\n

\u201cWe are pleased to be able to give start-ups the opportunity every year to present before top-class venture capital companies in order to establish contacts with investors at an early stage. I would very much like to thank our long-term partners, who leave with an extremely positive impression of the Munich start-up scene,” explains Dr. Peter Hanns Zobel, Managing Director of the IZB.<\/p>\n

\u201cWith the Munich Life Science Pitch Day we have established an outstanding event together with the IZB, Bayer AG and Boehringer Ingelheim, which has taken place for the sixth time in Munich. This is where partnerships emerge from which the life science start-ups and all participating investors benefit. At the same time, all participants gain valuable insights into the innovative strength of young start-ups. This is real added value for everyone involved. We are already looking forward to the next Pitch Day,\u201d according to Dr. Caroline Fichtner, Principal of HTF.<\/p>\n

\u201cThe Life Science Pitch Day offers the best possible framework for targeted networking with established investors. The ten participating life science start-ups impressed us with their innovative ideas. It was also a pleasure for me to round off the event in an interesting conversation with our guest Ingmar Hoerr, founder of CureVac,\u201d says Dr. Martin Pfister, Principal of HTGF.<\/p>\n

“A central aspect of a pitch event is networking. The founders have the chance to make important contacts with potential investors and partners. And it is precisely this exchange that is made possible at the Life Science Pitch Day in Munich. I was very impressed by the quality of the young start-ups’ research. It was great to follow the lively exchange and get to know the start-ups,” explains Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG.<\/p>\n

“At the Life Science Pitch Day, interesting partnerships and synergies can emerge between investor:ing and the innovative founder:ing scene. Events like these make a valuable contribution to promoting innovation and opening up new horizons for completely new therapeutic approaches for patients. The quality of the founding teams and the forward-looking solutions of the pitching start-ups are a real enrichment for the life science sector,” says Alexander Ehlgen, Boehringer Ingelheim Venture Fund.<\/p>\n

The investors were enthusiastic about the innovative drug developers. The following project teams presented at the “6th<\/sup> Munich Life Science Pitch Day”:<\/strong><\/p>\n

    \n
  1. Dimericon, Ulrich Kessler: Dimericon, Ulrich Kessler: Fighting cancer \u2013 A novel therapeutic modality conquering the plasticity conundrum in IDP-targeted oncology drug discovery<\/li>\n
  2. Fundamental Pharma, Thomas Schulze: Next generation brain drugs acting as molecular spacers to halt neurodegeneration<\/li>\n
  3. FUSIX Biotech, Jennifer Altomonte: A TUM spin-off developing a “best-in-class” oncolytic virus platform to treat solid tumors<\/li>\n
  4. Galimedix, Alexander Gebauer: Breakthrough therapy in Alzheimer\u00b4s disease:
    \nSmall molecule GAL-201 for cognitive improvement and neuroprotection<\/li>\n
  5. Intellexon, Christoph Winterhalter: Intellexon uncovered new embryo-fetal HLAs as unique tumor targets<\/li>\n
  6. Invasight, Karthiga Santhana Kumar: Developing potent and safe first-in-class, protein-protein interaction inhibitors against invasive cancers<\/li>\n
  7. OPSYON, Nadja Fenn: OPSYON’s vision and mission is to combine direct cancer cell targeting with the benefits of immune checkpoint inhibition in one molecule to maximize anti-cancer efficacy while minimizing unwanted side effects.<\/li>\n
  8. RecTec, Anne-Kristin Heninger: It is our vision to establish designer recombinases as the leading technology for safe and precise genome surgery to cure genetic diseases.<\/li>\n
  9. Riana Therapeutics, Anna Orlova: We develop novel first-in-class treatment options against cancer<\/li>\n
  10. Sirana Pharma, Hermann-Josef Kaiser: Restoring musculoskeletal health<\/li>\n<\/ol>\n

    [\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture<\/span> capital firms were enthusiastic about the quality of the<\/span><\/span><\/p>\n","protected":false},"author":8,"featured_media":18058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[843,1539,6402],"tags":[],"class_list":["post-18060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-izb-biotech-news","category-top-news"],"yoast_head":"\n6th Munich Life Science Pitch Day at the IZB with over 20 investors - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"description\" content=\"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"6th Munich Life Science Pitch Day at the IZB with over 20 investors\" \/>\n<meta property=\"og:description\" content=\"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-07T13:41:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-08T07:18:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"383\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"martin Reznicek\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"martin Reznicek\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/\"},\"author\":{\"name\":\"martin Reznicek\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/d8c3fdae36f92a8c67f39af096dd9437\"},\"headline\":\"6th Munich Life Science Pitch Day at the IZB with over 20 investors\",\"datePublished\":\"2021-10-07T13:41:38+00:00\",\"dateModified\":\"2021-10-08T07:18:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/\"},\"wordCount\":877,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/pitch-day-postjpg.jpg\",\"articleSection\":[\"Events\",\"IZB Biotech News\",\"Top News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/\",\"name\":\"6th Munich Life Science Pitch Day at the IZB with over 20 investors - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/pitch-day-postjpg.jpg\",\"datePublished\":\"2021-10-07T13:41:38+00:00\",\"dateModified\":\"2021-10-08T07:18:39+00:00\",\"description\":\"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/pitch-day-postjpg.jpg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/pitch-day-postjpg.jpg\",\"width\":600,\"height\":383},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZB Biotech News\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/izb-biotech-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"6th Munich Life Science Pitch Day at the IZB with over 20 investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/d8c3fdae36f92a8c67f39af096dd9437\",\"name\":\"martin Reznicek\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"6th Munich Life Science Pitch Day at the IZB with over 20 investors - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/","og_locale":"en_US","og_type":"article","og_title":"6th Munich Life Science Pitch Day at the IZB with over 20 investors","og_description":"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research","og_url":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_published_time":"2021-10-07T13:41:38+00:00","article_modified_time":"2021-10-08T07:18:39+00:00","og_image":[{"width":600,"height":383,"url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg","type":"image\/jpeg"}],"author":"martin Reznicek","twitter_card":"summary_large_image","twitter_misc":{"Written by":"martin Reznicek","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#article","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/"},"author":{"name":"martin Reznicek","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/d8c3fdae36f92a8c67f39af096dd9437"},"headline":"6th Munich Life Science Pitch Day at the IZB with over 20 investors","datePublished":"2021-10-07T13:41:38+00:00","dateModified":"2021-10-08T07:18:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/"},"wordCount":877,"commentCount":0,"publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg","articleSection":["Events","IZB Biotech News","Top News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/","url":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/","name":"6th Munich Life Science Pitch Day at the IZB with over 20 investors - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg","datePublished":"2021-10-07T13:41:38+00:00","dateModified":"2021-10-08T07:18:39+00:00","description":"The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#primaryimage","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/10\/pitch-day-postjpg.jpg","width":600,"height":383},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/6th-munich-life-science-pitch-day-at-the-izb-with-over-20-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZB Biotech News","item":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/"},{"@type":"ListItem","position":3,"name":"6th Munich Life Science Pitch Day at the IZB with over 20 investors"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/d8c3fdae36f92a8c67f39af096dd9437","name":"martin Reznicek"}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/18060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/comments?post=18060"}],"version-history":[{"count":7,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/18060\/revisions"}],"predecessor-version":[{"id":18140,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/18060\/revisions\/18140"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media\/18058"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=18060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/categories?post=18060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/tags?post=18060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}